Genocea Biosciences Inc. (NASDAQ:GNCA)’s share price was down 3.6% during mid-day trading on Thursday . The stock traded as low as $4.05 and last traded at $4.07, with a volume of 152,690 shares changing hands. The stock had previously closed at $4.22.

Several equities analysts recently issued reports on GNCA shares. Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of Genocea Biosciences in a report on Friday, April 1st. Stifel Nicolaus boosted their target price on shares of Genocea Biosciences from $11.00 to $13.00 and gave the company a “buy” rating in a report on Friday, April 1st. FBR & Co restated a “buy” rating on shares of Genocea Biosciences in a report on Friday, June 10th. Finally, Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a report on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $18.13.

The company’s market capitalization is $114.58 million. The firm’s 50 day moving average is $4.14 and its 200-day moving average is $4.27.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.07. On average, analysts predict that Genocea Biosciences Inc. will post ($1.74) EPS for the current year.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.